Publication: A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients
Issued Date
2011
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
BioMed Central
Bibliographic Citation
Journal of Hematology & Oncology. Vol. 4, (2011), 7
Suggested Citation
Wanwisa Wongboonma, Wanna Thongnoppakhun, Chirayu U Auewarakul A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. Journal of Hematology & Oncology. Vol. 4, (2011), 7. doi:10.1186/1756-8722-4-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/2644
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients
Other Contributor(s)
Abstract
Background: BCR-ABL kinase domain (KD) mutation is the major mechanism contributing to suboptimal response
to tyrosine kinase inhibitors (TKI) in BCR-ABL-positive chronic myeloid leukemia (CML) patients. T315I mutation, as
one of the most frequent KD mutations, has been shown to be strongly associated with TKI resistance and
subsequent therapeutic failure. A simple and sensitive method is thus required to detect T315I mutation at the
earliest stage.
Methods: A single-tube allele specific-polymerase chain reaction (AS-PCR) method was developed to detect T315I
mutation in a mixture of normal and mutant alleles of varying dilutions. Denaturing high performance liquid
chromatography (DHPLC) and direct sequencing were performed as a comparison to AS-PCR.
Results: T315I mutant bands were observed in the mixtures containing as low as 0.5-1% of mutant alleles by
AS-PCR. The detection sensitivity of DHPLC was around 1.5-3% dilution whereas sequencing analysis was unable to
detect below 6.25% dilution.
Conclusion: A single-tube AS-PCR is a rapid and sensitive screening method for T315I mutation. Detection of the
most resistant leukemic clone in CML patients undergoing TKI therapy should be feasible with this simple and
inexpensive method.